Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Scailyte is a Swiss ETH Zurich spin-off that specializes in the application of artificial intelligence (AI) and proprietary single-cell data analysis algorithms to discover novel and ultra-sensitive biomarkers. Their cutting-edge platform aims to accelerate drug development, improve diagnostics, and enable precision medicine, with a primary focus on complex diseases in areas like oncology and immunology. By identifying unique biological signatures, Scailyte helps to stratify patients, predict treatment responses, and uncover new therapeutic targets.
The Eschlikon headquarters serves as the primary center for Scailyte's strategic operations, corporate management, and core research and development activities in AI-driven biomarker discovery.
Likely equipped with modern office spaces and advanced computational infrastructure necessary for handling large-scale single-cell datasets and running complex AI algorithms. It may also include or be near facilities for biological sample processing and validation.
As an ETH Zurich spin-off, Scailyte's work culture is characterized by innovation, scientific rigor, and collaboration. It fosters a dynamic environment where data scientists, biologists, and clinicians work together on cutting-edge precision medicine solutions.
The Swiss headquarters provides Scailyte with access to a highly skilled talent pool, a robust network of research institutions (including its ETH Zurich roots), and a supportive regulatory and business environment for biotech innovation.
While Scailyte's core operations are based in Switzerland, its impact and collaborations are global. The company partners with pharmaceutical firms, clinical research organizations, and academic institutions worldwide to apply its AI-driven biomarker discovery platform in diverse therapeutic areas. Scailyte also maintains Scailyte USA, Inc., indicating strategic interests and activities in the North American market, particularly for clinical studies and commercial partnerships.
Hörnlistrasse 14
Eschlikon
Thurgau
Switzerland
Address: Murtschenstrasse 39, 8048 Zürich
Facilitates direct engagement with academic partners, access to specialized talent, and participation in the Greater Zurich Area's innovation ecosystem, particularly in life sciences and AI.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, scailyte' leadership includes:
scailyte has been backed by several prominent investors over the years, including:
Over the past year, Scailyte significantly bolstered its commercial leadership by appointing Kieran O'Mahony as Chief Commercial Officer. No other major C-suite executive departures have been publicly announced during this period.
Discover the tools scailyte uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Scailyte commonly uses the email format [first].[last]@scailyte.com for its professional communications. This structure is prevalent in many technology and biotechnology companies, facilitating straightforward contact.
[first].[last]@scailyte.com
Format
peter.nestorov@scailyte.com
Example
90%
Success rate
Scailyte Official Website • February 20, 2024
Scailyte AG and ONWARD Medical N.V. have formed a strategic partnership to develop prognostic and predictive biomarkers for ONWARD’s ARC-EX® Therapy, which aims to restore movement and function for individuals with spinal cord injury (SCI)....more
Scailyte Official Website • September 12, 2023
Scailyte announced the strategic appointment of Kieran O’Mahony as its new Chief Commercial Officer. He will lead Scailyte’s commercial strategy, business development, and market expansion efforts for its AI-driven biomarker solutions....more
Scailyte Official Website • June 20, 2023
Scailyte revealed it would present significant findings from its AI-powered research into novel biomarkers for endometriosis at the 39th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE), highlighting potential for improved diagnostics....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including scailyte, are just a search away.